Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Affordable Access

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Publisher
BioMed Central
Publication Date
Jan 01, 2004
Source
PMC
Keywords
Disciplines
  • Medicine
License
Unknown

Abstract

R82 Critical Care April 2004 Vol 8 No 2 Kinasewitz et al. Research Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] Gary T Kinasewitz1, S Betty Yan2, Bruce Basson2, Philip Comp1, James A Russell3, Alain Cariou4, Suzane L Um2, Barbara Utterback2, Pierre-Francois Laterre5 and Jean-François Dhainaut4, for the PROWESS Sepsis Study Group 1Department of Medicine, Physiology and Biophysics, University of Oklahoma Health Science Center, and Cardiovascular Biology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA 3St Paul’s Hospital, Vancouver, British Columbia, Canada 4Service de Réanimation Médicale, Centre Hospitalo-Universitaire Cochin Port-Royal, AP-HP, Paris V University, Paris, France 5Cliniques Universitares St. Luc, Brussels, Belgium Correspondence: S Betty Yan, [email protected] α2-AP = α2-antiplasmin; APACHE = Acute Physiology and Chronic Health Evaluation; APTT = activated partial thromboplastin time; F1.2 = prothrombin fragment F1.2; IL = interleukin; PAI = plasminogen activator inhibitor; PROWESS = Recombinant Human Activated Protein C World- wide Evaluation in Severe Sepsis; PT = prothrombin time; sTM = soluble thrombomodulin; TAFI = thrombin activatable fibrinolysis inhibitor; TAT = thrombin–antithrombin complex; TNF = tumor necrosis factor. Abstract Introduction PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) was a phase III, randomized, double blind, placebo controlled, multicenter trial conducted in patients with severe sepsis from 164 medical centers. Here we report data collected at study entry for 1690 patients and over the following 7 days for the 840 patients who received placebo (in addition to usual standard of care). Methods Nineteen biomarkers of coagulation activation, anticoagulation, fibrinolysis, endothel

Report this publication

Statistics

Seen <100 times